ASCO GU 2019

ASCO GU COMPLETE COVERAGE

Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma

By

Jody A. Charnow

Compared with sorafenib, tivozanib was associated with improved progression-free survival and objective response rate, researchers reported.

First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC

By

Jody A. Charnow

About 25% of patients with previously untreated advanced non-clear cell renal cell carcinoma had an objective response to pembrolizumab.

Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma

By

Jody A. Charnow

New analysis shows that early tumor shrinkage with cabozantinib is associated with longer survival compared with everolimus.

Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma

By

Jody A. Charnow

Avelumab-axitinib regimen offers better progression-free survival and responses than sunitinib for patients with previously untreated advanced RCC, regardless of risk group or PD-L1 status.

Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed

By

Jody A. Charnow

Patients with treatment-naive, intermediate- and poor-risk advanced RCC continue to have superior overall survival with the dual ICI regimen compared with sunitinib alone.

Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma

By

Jody A. Charnow

As first-line therapy for locally advanced or metastatic renal cell carcinoma, pembrolizumab plus axitinib offers longer overall and progression-free survival compared with sunitinib.

Adding Chemotherapy to Radiation Post-Radical Cystectomy Improves Survival in Urothelial Carcinoma

By

Jody A. Charnow

Postoperative radiation therapy with adjuvant chemotherapy prolonged disease-free survival and overall survival in patients with locally advanced urothelial carcinoma.

Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma

By

Jody A. Charnow

In a study of patients receiving non-surgical treatment for localized upper tract urothelial carcinoma, radiation or chemotherapy provided no overall survival benefit.

Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer

By

Jody A. Charnow

Trimodal therapy for patients with muscle-invasive bladder cancer is associated with worse cancer-specific and overall survival and higher costs compared with radical cystectomy.

Pembrolizumab Shows Promise for BCG-Unresponsive Bladder Cancer

By

Jody A. Charnow

Pembrolizumab, a PD-1 inhibitor, demonstrated antitumor activity in patients with high-risk BCG-unresponsive carcinoma in situ.

Bladder Cancer Response to Bacillus Calmette-Guérin May Be Linked to Urine Microbiome

By

Jody A. Charnow

New evidence suggests variation in the bacterial composition of urine is associated with response BCG among patients with non-muscle-invasive bladder cancer.

Investigational Antiandrogen Drug Delays Metastasis in CRPC

By

Jody A. Charnow

Among men with nonmetastatic castration-resistant prostate cancer, those who were treated with darolutamide had a 59% decreased risk of metastasis compared with placebo recipients.

Abiraterone, Prednisone With Androgen Deprivation Therapy Show Durable Efficacy in Metastatic Castration-Naive Prostate Cancer

By

Jody A. Charnow

At a median follow-up of nearly 52 months, the treatment regimen deceased mortality risk among men with high-risk metastatic castration-naive prostate cancer by 30%.

Trial Update for Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer

By

Jody A. Charnow

After an additional 1 year of follow-up, apalutamide plus ADT continued to show a significant decrease in the risk of progression to metastasis or death.

Newer mCRPC Drugs Led to Longer Survival in African American Patients

By

Jody A. Charnow

The study is the first to show that treatment with abiraterone acetate/enzalutamide is associated with better survival in African American patients with mCRPC compared with Caucasians.

Metastatic Prostate Cancer Responds to Novel Radiation Therapy

By

Jody A. Charnow

By targeting prostate-specific membrane antigen, a molecule radiolabeled with lutetium-177 is expected to deliver high doses of beta radiation to distant metastases.

PCa Genomic Test May Predict Outcomes More Accurately in African-American Men

By

Jody A. Charnow

The Decipher genomic classifier predicted metastases and prostate cancer-specific mortality following radical prostatectomy with greater precision in African-American men.